Phenotypic and immunological profile divergence between SLE-associated myelitis and SLE-NMOSD overlap syndrome: a retrospective case series
Frontiers in Immunology · 2026
DOI: 10.3389/fimmu.2026.1925485 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, 2026. Verfasst von Tingting Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, First Affiliated Hospital of Dalian Medical University, Dalian, China. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Neuromyelitis Optica, Myelitis. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Systemic lupus erythematosus-associated myelitis (SLE-AM) is a devastating neuroimmunological complication. Increasing evidence suggests that myelitis occurring in patients with SLE is heterogeneous and may include non-overlap SLE-AM and SLE-neuromyelitis optica spectrum disorder (NMOSD) overlap syndrome. We aimed to describe the clinical, radiological, CSF inflammatory and systemic immunological profiles of patients with these conditions and to explore their potential therapeutic implications.
Methods
We conducted a retrospective, single-center case series of six patients with SLE-associated myelitis treated at the First Affiliated Hospital of Dalian Medical University. Two patients were classified as having non-overlap SLE-AM and four as having SLE-NMOSD overlap syndrome according to clinical, radiological, and serological findings.
Results
Among the six patients, five were women and one was a man; Patients 1 and 2 had non-overlap SLE-AM, whereas Patients 3–6 had SLE-NMOSD overlap syndrome. In Patients 1 and 2, myelitis occurred concurrently with SLE onset and was accompanied by marked cerebrospinal fluid (CSF) inflammation, high anti-dsDNA antibody levels, and complement consumption. Patients 3–6 had more heterogeneous temporal courses and generally lower routine CSF inflammatory indices; serum AQP4-IgG was positive in Patients 4–6 and was not tested in Patient 3. Despite intensive immunosuppressive treatment, several patients had substantial residual neurological disability during follow-up. Notably, Patient 4 showed improvement in left-leg pain and remained clinically stable, with no recurrence over nearly 7 months of follow-up after inebilizumab treatment.
Conclusion
Non-overlap SLE-AM and SLE-NMOSD overlap syndrome may show differing clinical and CSF profiles. Detailed serological and CSF characterization may help distinguish these clinical patterns and inform more individualized therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Zitieren
APA
Zhang, T., Liu, Q., Cong, H., Huang, Y., & Zhang, H. (2026). Phenotypic and immunological profile divergence between SLE-associated myelitis and SLE-NMOSD overlap syndrome: a retrospective case series. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1925485
Vancouver
Zhang T, Liu Q, Cong H, Huang Y, Zhang H. Phenotypic and immunological profile divergence between SLE-associated myelitis and SLE-NMOSD overlap syndrome: a retrospective case series. Frontiers in Immunology. 2026. doi:10.3389/fimmu.2026.1925485
BibTeX
@article{Zhang2026,
author = {Zhang, Tingting and Liu, Qingmiao and Cong, Hui and Huang, Yiling and Zhang, Hui},
title = {Phenotypic and immunological profile divergence between SLE-associated myelitis and SLE-NMOSD overlap syndrome: a retrospective case series},
journal = {Frontiers in Immunology},
year = {2026},
doi = {10.3389/fimmu.2026.1925485}
}
EUVIMED